Corpus overview


MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

There are no SARS-CoV-2 protein terms in the subcorpus


SARS-CoV-2 Proteins
    displaying 1 - 10 records in total 17
    records per page

    Prophylaxis for covid-19 MESHD: living systematic review and network meta-analysis

    Authors: Jessica J Bartoszko; Reed AC Siemieniuk; Elena Kum; Anila Qasim; Dena Zeraatkar; Long Ge; Mi Ah Han; Behnam Sadeghirad; Arnav Agarwal; Thomas Agoritsas; Derek K Chu; Rachel Couban; Andrea J Darzi; Tahira Devji; Maryam Ghadimi; Kimia Honarmand; Ariel Izcovich; Assem Khamis; Francois Lamontagne; Mark Loeb; Maura Marcucci; Shelley L McLeod; Shahrzad Motaghi; Srinivas Murthy; Reem A Mustafa; John D Neary; Hector Pardo-Hernandez; Gabriel Rada; Bram Rochwerg; Charlotte Switzer; Britta Tendal; Lehana Thabane; Per O Vandvik; Robin WM Vernooij; Andres Viteri-Garcia; Ying Wang; Liang Yao; Zhikang Ye; Gordon H Guyatt; Romina Brignardello-Petersen

    doi:10.1101/2021.02.24.21250469 Date: 2021-02-26 Source: medRxiv

    Objective To determine and compare the effects of drug prophylaxis on severe acute respiratory syndrome coronavirus virus 2 (SARS-CoV-2) infection MESHD and coronavirus disease 2019 MESHD ( covid-19 MESHD). Design Living systematic review and network meta-analysis. Data sources WHO covid-19 MESHD database, a comprehensive multilingual source of global covid-19 MESHD literature to 19 January 2021, and six additional Chinese databases to 20 January 2021. Study selection Randomized trials in which people at risk of covid-19 MESHD were randomized to drug prophylaxis or no prophylaxis (standard care or placebo). Pairs of reviewers independently screened potentially eligible articles. Methods After duplicate data abstraction, we conducted random-effects bayesian network meta-analysis. We assessed risk of bias of the included studies using a modification of the Cochrane risk of bias 2.0 tool and assessed the certainty of the evidence using the grading of recommendations assessment, development and evaluation (GRADE) approach. Results The first iteration of this living network meta-analysis includes nine randomized trials: six addressing hydroxychloroquine (6,059 participants), one addressing ivermectin combined with iota-carrageenan (234 participants) and two addressing ivermectin alone (540 participants), all compared to standard care or placebo. Hydroxychloroquine has no important effect on admission to hospital (risk difference (RD) 1 fewer per 1,000, 95% credible interval (CrI) 3 fewer to 4 more, high certainty) or mortality (RD 1 fewer per 1,000, 95% CrI 2 HGNC fewer to 3 more, high certainty). Hydroxychloroquine probably has no important effect on laboratory-confirmed infection (RD 2 more per 1,000, 95% CrI 18 fewer to 28 more, moderate certainty), probably increases adverse effects leading to drug discontinuation (RD 19 more per 1,000, 95% CrI 1 HGNC fewer to 70 more, moderate certainty) and may have no important effect on suspected, probable or laboratory-confirmed infection (RD 15 fewer per 1,000, 95% CrI 64 fewer to 41 more, low certainty). Due to serious risk of bias and very serious imprecision, and thus very low certainty evidence, the effects of ivermectin combined with iota-carrageenan on laboratory-confirmed infection (RD 52 fewer per 1,000, 95% CrI 58 fewer to 37 fewer), and ivermectin alone on laboratory-confirmed infection (RD 50 fewer per 1,000, 95% CrI 59 fewer to 16 fewer) and suspected, probable or laboratory-confirmed infection MESHD (RD 159 fewer per 1,000, 95% CrI 165 fewer to 144 fewer) remain uncertain. Conclusion Hydroxychloroquine prophylaxis does not have an important effect on hospital admission and mortality, probably increases adverse effects, and probably does not have an important effect on laboratory-confirmed SARS-CoV-2 infection MESHD. Because of serious risk of bias and very serious imprecision, we are highly uncertain whether ivermectin combined with iota-carrageenan and ivermectin alone reduce the risk of SARS-CoV-2 infection MESHD. Systematic review registration This review was not registered. The protocol established a priori is included as a supplement. Funding This study was supported by the Canadian Institutes of Health Research (grant CIHR-IRSC:0579001321). Reader note This article is a living systematic review that will be updated to reflect emerging evidence. Updates may occur for up to two years from the date of original publication.

    High Dimensional Characterization of Post-acute Sequalae of COVID-19 MESHD: analysis of health outcomes and clinical manifestations at 6 months

    Authors: Ziyad Al-Aly; Yan Xie; Benjamin Bowe

    doi:10.21203/ Date: 2021-01-19 Source: ResearchSquare

    The coronavirus disease 2019 MESHD ( COVID-19 MESHD) is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 MESHD. The acute clinical manifestations of COVID-19 MESHD are well characterized. The post-acute sequalae of COVID-19 MESHD have not been comprehensively described. Here, we use the national healthcare databases of the US Department of Veterans Affairs to undertake a high dimensional approach to comprehensively identify 6-months outcomes of incident clinical manifestations including diagnoses, medication use, and laboratory abnormalities MESHD in people who survived the first 30 days of COVID-19 MESHD. We first describe the clinical manifestations in people with COVID-19 MESHD compared to users of the Veterans Affairs healthcare system. We then provide a comparative evaluation of the post-acute sequalae in 30-day survivors who were hospitalized for COVID-19 MESHD vs. seasonal influenza. We show that beyond the first 30 days of illness, people with COVID-19 MESHD are at higher risk of death MESHD and health resource utilization. Our approach identifies incident clinical manifestations in the respiratory system and several other manifestations including the nervous system and neurocognitive disorders MESHD, mental health disorders, metabolic disorders MESHD, cardiovascular disorders MESHD, gastrointestinal disorders MESHD, and signs and symptoms related to poor generalized wellbeing including malaise, fatigue MESHD, musculoskeletal pain MESHD, and anemia MESHD. There was increased incident use of pain MESHD medications (opioids and non-opioids), antidepressants, anxiolytics, antihypertensives, antihyperlipidemic, insulin HGNC, and several other medication classes. The findings show that beyond the first 30 days of illness, substantial burden of health loss — spanning pulmonary and several extrapulmonary organ systems — is experienced by COVID-19 MESHD survivors. The results provide a roadmap to inform health system planning and development of multidisciplinary care strategies aimed at reducing chronic health loss and optimizing wellness among COVID-19 MESHD survivors.

    Characteristics and outcomes of hospitalized adult COVID-19 MESHD patients in Georgia

    Authors: Tengiz Tsertsvadze; Marina Ezugbaia; Marina Endeladze; Levani Ratiani; Neli Javakhishvili; Lika Mumladze; Manana Khotcholava; Maiko Janashia; Diana Zviadadze; Levan Gopodze; Alex Gokhelashvili; Revaz Metchurchtlishvili; Akaki Abutidze; Nikoloz Chkhartishvili

    doi:10.1101/2020.10.23.20218255 Date: 2020-10-27 Source: medRxiv

    Objective: Describe presenting characteristics of hospitalized patients and explore factors associated with in-hospital mortality during the first wave of pandemic in Georgia. Methods: This retrospective study included 582 adult patients admitted to 9 dedicated COVID-19 MESHD hospitals as of July 30, 2020 (72% of all hospitalizations). Data were abstracted from medical charts. Factors associated with mortality were evaluated in multivariable Poisson regression analysis. Results: Among 582 adults included in this analysis 14.9% were 65+ years old, 49.1% were women, 59.3% had uni- or bi-lateral lung involvement on chest computed tomography, 27.1% had any co-morbidity, 13.2% patients had lymphopenia MESHD, 4.1% had neutophilosis, 4.8% had low platelet count, 37.6% had d-dimer levels of >0.5 mcg/l. Overall mortality was 2.1% (12/582). After excluding mild infections, mortality among patients with moderate-to-critical disease was 3.0% (12/399), while among patients with severe-to-critical disease mortality was 12.7% (8/63). Baseline characteristics associated with increased risk of mortality in multivariate regression analysis included: age [≥]65 years (RR: 10.38, 95% CI: 1.30-82.75), presence of any chronic co-morbidity (RR: 20.71, 95% CI: 1.58-270.99), lymphopenia MESHD (RR: 4.76, 95% CI: 1.52-14.93), neutrophilosis (RR: 7.22, 95% CI: 1.27-41.12), low platelet count (RR: 6.92, 95% CI: 1.18-40.54), elevated d-dimer (RR: 4.45, 95% CI: 1.48-13.35), elevated AST HGNC (RR: 6.33, 95% CI: 1.18-33.98). Conclusion: In-hospital mortality during the first wave of pandemic in Georgia was low. We identified several risk factors (older age, co-morbidities and laboratory abnormalities MESHD) associated with poor outcome that should provide guidance for planning health sector response as pandemic continues to evolve.

    Identification of immunological, inflammatory, hematological, and coagulation abnormalities associated with severity and mortality of COVID-19 MESHD: a meta-analysis of 64 observational studies

    Authors: Li He; Rundong Qin; Zhaowei Yang; Nan Jia; Ruchong Chen; Jiaxing Xie; Wanyi Fu; Hao Chen; Xinliu Lin; Renbin Huang; Tian Luo; Yukai Liu; Siyang Yao; Mei Jiang; Jing Li

    doi:10.21203/ Date: 2020-09-08 Source: ResearchSquare

    BackgroundLaboratory abnormalities associated with disease severity and mortality in patients with coronavirus disease 2019 MESHD ( COVID-19 MESHD) have been reported in many observational studies. However, there are significant heterogeneities in patient characteristics and research methodologies in these studies.ObjectivesWe aimed to provide an updated synthesis of the association between laboratory abnormalities MESHD and COVID-19 MESHD prognosis.MethodsWe conducted an electronic search of PubMed, Scopus, Ovid, Willey, Web of Science, and the China National Knowledge Infrastructure (CNKI) for studies reporting hematological, coagulation, inflammatory, and immunological results during hospital admission of COVID-19 MESHD patients with different severities and outcomes.ResultsA total of 64 studies were included in the current meta-analysis, with 8 hematological, 3 coagulation, 5 inflammatory, and 23 immunological variables reported. Of them, white blood cell (WBC) and neutrophil counts ( Neu HGNC), D-dimer level, procalcitonin (PCT), erythrocyte sedimentation rate (ESR), C-reactive protein HGNC ( CRP HGNC), ferretin, serum amyloid A (SAA), interleukins (ILs)–2R, IL-6 HGNC, and IL-10 HGNC were significantly increased in severely ill patients and non-survivors. Meanwhile, non-severely ill patients and survivors presented significantly higher counts of eosinophils, lymphocytes, and CD4+ and CD8+ T cells. A majority of included variables presented with significant heterogeneity, some of which resulted from differing disease severities and ages of included patients.ConclusionsThe current meta-analysis provides a comprehensive and updated synthesis of the association between admission laboratory abnormalities with severity and mortality of COVID-19 MESHD. Our results highlight that increases in the levels of PCT, ESR, CRP HGNC, ferretin, SAA, IL-2R HGNC, IL-6 HGNC, and IL-10 HGNC were associated with disease deterioration, whereas elevated eosinophils, lymphocytes, and T-cell subsets might serve as indicators of favorable outcomes.

    Older adults hospitalized with Covid-19 MESHD: Clinical characteristics and early outcomes from a single center in Istanbul, Turkey 

    Authors: Alpay Medetalibeyoğlu; Naci Senkal; Murat Kose; Yunus Catma; Emine Bilge Caparali; Mustafa Erelel; Mustafa Oral Oncul; Gulistan Bahat; Tufan Tukek

    doi:10.21203/ Date: 2020-07-22 Source: ResearchSquare

    Objective: Older adults have been continuously reported to be at higher risk for adverse outcomes of Covid-19 MESHD. We aimed to describe clinical characteristics and early outcomes of the older Covid-19 MESHD patients hospitalized in our center comparatively with the younger patients, and also to analyze the triage factors that were related to the in-hospital mortality of older adults.Design: Retrospective; observational studySetting: Istanbul Faculty of Medicine hospital, TurkeyParticipants: 362 hospitalized patients with laboratory-confirmed Covid-19 MESHD from March 11 to May 11, 2020.Measurements: The demographic information; associated comorbidities; presenting clinical, laboratory, radiological characteristics on admission and outcomes from the electronic medical records were analyzed comparatively between the younger (<65 years) and older (≥65 years) adults. Factors associated with in-hospital mortality of the older adults were analyzed by multivariate regression analyses.Results: The median age was 56 years (interquartile range [IQR], 46-67), and 224 (61.9%) were male. There were 104 (28.7%) patients ≥65 years of age. More than half of the patients (58%) had one or more chronic comorbidity. The three most common presenting symptoms in the older patients were f atigue/ MESHDm yalgia MESHD(89.4%), d ry cough MESHD(72.1%), and f ever MESHD(63.5%). Cough and f ever MESHDwere significantly less prevalent in older adults compared to younger patients (p=0.001 and 0.008, respectively). Clinically severe p neumonia MESHDwas present in 31.5% of the study population being more common in older adults (49% vs. 24.4%) (p<0.001). The laboratory parameters that were significantly different between the older and younger adults were as follows: the older patients had significantly higher CRP, D-dimer, T nT, HGNC pro-BNP, procalcitonin levels, higher prevalence of l ymphopenia, MESHD neutrophilia, increased creatinine, and lower hemoglobin, ALT, a lbumin HGNClevel (p<0.05). In the radiological evaluation, more than half of the patients (54.6%) had moderate-severe p neumonia, MESHD which was more prevalent in older patients (66% vs. 50%) (p=0.006). The adverse outcomes were significantly more prevalent in older adults compared to the younger patients (ICU admission, 28.8% vs. 8.9%; mortality, 23.1% vs. 4.3%, p<0.001).  Among the triage evaluation parameters, the only factor associated with higher mortality was the presence of clinically severe p neumonia MESHDon admission (Odds Ratio=12.3, 95% confidence interval=2.7-55.5, p=0.001).Conclusion: Older patients presented with more prevalent chronic comorbidities, less prevalent symptomatology but more severe respiratory signs and l aboratory abnormalities MESHDthan the younger patients. Among the triage assessment factors, the clinical evaluation of pulmonary involvement came in front to help clinicians to stratify the patients for mortality risk.

    Clinical Characteristics of Non-Pneumonia COVID-19 MESHD Adults in Shanghai, China

    Authors: Haiying Ji; Lijuan Hu; Tao Li; Linjing Gong; Xu Wu; Qinjun Shen; Zhilong Jiang; Lei Zhu

    doi:10.21203/ Date: 2020-06-19 Source: ResearchSquare

    Background: Since December 2019, coronavirus disease 2019 MESHD ( COVID-19 MESHD) rapidly spread throughout the whole world , data have been needed on the clinical characteristics of the affected patients.Objectives: A total of 579 adult COVID-19 MESHD cases were enrolled in Shanghai from Jan 20 to Apr HGNC 15, 2020, in which 95 cases (16.41%) showed non-pneumonia on CT when confirmed. The characteristics of non-pneumonia cases have not been clearly described previously, and this might provide guidance to prevent and treatment of COVID-19 MESHD.Method: We retrospectively collected the patient clinical dataset including demography, epidemiology, clinical manifestation, laboratory test results, diagnostic classification, treatment and clinical outcomes.Results: The average age of 95 COVID-19 MESHD cases was 31.45 ± 12.89 years old and 95.79% of them were less than 60 years old. They had mild clinical symptoms and/or laboratory abnormalities MESHD. 20 of the 95 cases occurred mild pneumonia MESHD during hospitalization, accompanied with lower lymphocyte counts, in which 60% cases were complicated with underlying condition and 15% cases were over 60 years old. All cases were cured. 16 of the 95 cases were local residents with clear epidemiological history and long incubation time, and mainly discovered as fever MESHD and respiratory symptoms. Other 79 cases were overseas imported, some had initial symptoms of diarrhea MESHD, smell or taste disorders MESHD and so on. They were mainly found at port of entry.Conclusions: Non-pneumonia COVID-19 MESHD predominantly occurred among young adults with mild clinical symptoms and possible long incubation time. The patients with underlying condition or at older age more likely developed mild pneumonia MESHD after diagnosis. Thereby, it is very important to pay attention to these patients and make reasonable diagnostic classification towards better prevention and treatment of COVID-19 MESHD.

    Assessment of Inactivation Procedures for SARS-CoV-2

    Authors: Heidi Auerswald; Sokhoun Yann; Sokha Dul; Saraden In; Philippe Dussart; Nicholas J Martin; Erik A Karlsson; Jose A Garcia-Rivera

    doi:10.1101/2020.05.28.120444 Date: 2020-05-28 Source: bioRxiv

    Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the causative agent of Coronavirus disease 2019 MESHD ( COVID-19 MESHD), presents a challenge to laboratorians and healthcare workers around the world. Handling of biological samples from individuals infected with the SARS-CoV-2 virus requires strict biosafety and biosecurity measures. Within the laboratory, non-propagative work with samples containing the virus requires, at minimum, Biosafety Level-2 (BSL-2) techniques and facilities. Therefore, handling of SARS-CoV-2 samples remains a major concern in areas and conditions where biosafety and biosecurity for specimen handling is difficult to maintain, such as in rural laboratories MESHD or austere field testing sites. Inactivation through physical or chemical means can reduce the risk of handling live virus and increase testing ability worldwide. Herein we assess several chemical and physical inactivation techniques employed against SARS-CoV-2 isolates from Cambodian COVID-19 MESHD patients. This data demonstrates that all chemical (AVL, inactivating sample buffer and formaldehyde) and heat treatment (56{degrees}C and 98{degrees}C) methods tested completely inactivated viral loads of up to 5 log10.

    Vasculitis-Associated Auto-antibodies and Complement Levels in patients with COVID-19 MESHD Infection 

    Authors: Maryam Mobini; Roya Ghasemian; Laleh Vahedi Larijani; Maeede Mataji; Iradj Maleki

    doi:10.21203/ Date: 2020-05-21 Source: ResearchSquare

    Introduction / objectives: The cause of coronavirus disease 2019 MESHD ( COVID-19 MESHD) is severe acute r espiratory syndrome MESHD2 (SARS-CoV-2). There are evidences of involvement of immune system in pathogenesis of this disease. We investigated the presence of various v asculitis- MESHDassociated auto-antibodies and complement levels in a series of patients with COVID-19 MESHD i nfection MESHDadmitted to our hospital.Methods: Forty patients with severe or critical type of COVID 19 were evaluated for symptoms, signs and laboratory tests of v asculitis syndromes MESHDincluding r heumatoid MESHDfactor (RF), anti-nuclear antibody (ANA), anti dsDNA, c and p anti-neutrophilic cytoplasmic antibody (c ANCA HGNCand p ANCA) and complement levels. Descriptive statistics methods were used to describe the clinical / laboratory findings.Results: Forty patients with severe to c ritical illness MESHDwere enrolled in the study. The mean age of the patients was 48.5 ± 9.8 years. All patients had pulmonary involvement in lung CT scan. L ymphopenia MESHDin 19 (47.5%), raised creatinine in 8(20%) and h yperbilirubinemia MESHDin 19(47.5%) of patients were seen. V asculitis laboratory MESHDtest results included: RF in 2 patients, ANA in 3 patients and ANCA in one patient. 17(42.5%) of patients had hypocomplementemia in one or more complement tests. Of the four patients who were expired, three had a decrease in complement.Conclusion: In 17 of patients (42.5%) we detected low complement levels. A decrease in complement levels may predict a critical state of the disease. Therefore, measuring its levels may be helpful in making earlier decisions to initiate disease-suppressing treatments, including corticosteroids and IVIG.

    Characteristics and outcome of SARS-CoV-2 infection MESHD in cancer patients.

    Authors: Clemence Basse; Sarah Diakite; Vincent Servois; Maxime Frelaut; Aurelien Noret; Audrey Bellesoeur; Pauline Moreau; Marie-Ange Massiani; Anne-Sophie Bouyer; perrine vuagnat; SAndra Malak; Francois-Clement Bidard; Dominique Vanjak; Irene Kriegel; Alexis Burnod; Geoffroy Bilger; Toulsie Ramtohul; Gille Dhonneur; Carole Bouleuc; Nathalie Cassoux; Xavier Paoletti; Laurence Bozec; Paul Cottu

    doi:10.1101/2020.05.14.20101576 Date: 2020-05-19 Source: medRxiv

    Abstract Background: Concerns have emerged about the higher risk of fatal COVID-19 MESHD in cancer MESHD patients. In this paper, we review the experience of a comprehensive cancer MESHD center. Methods: A prospective registry was set up at Institut Curie at the beginning of the COVID-19 pandemic MESHD. All cancer MESHD patients with suspected or proven COVID-19 MESHD were entered and actively followed for 28 days. Results: Among 9,842 patients treated at Institut Curie between mid-March and early May 2020, 141 (1.4%) were diagnosed with COVID-19 MESHD, based on RT-PCR testing and/or CT-scan. In line with our case-mix, breast cancer MESHD (40%) was the most common tumor MESHD type, followed by hematological and lung malignancies MESHD (both 13%). Patients with active cancer MESHD therapy or/and advanced cancer MESHD accounted for 88% and 69% of patients, respectively. At diagnosis, 79% of patients had COVID-19 MESHD related symptoms, with an extent of lung parenchyma involvement [≤]50% in 90% of patients. Blood count variations and C-reactive protein elevation were the most common laboratory abnormalities MESHD. Antibiotics and antiviral agents were administered in 48% and 7% of patients, respectively. At the time of analysis, 26 patients (18%) have died from COVID-19 MESHD, and 81 (57%) were cured. Independent prognostic factors at the time of COVID-19 MESHD diagnosis associated with death MESHD or intensive care unit admission were extent of COVID-19 MESHD pneumonia MESHD and decreased O2 saturation. Conclusions: COVID-19 MESHD incidence and presentation in cancer MESHD patients appear to be very similar to those in the general population. The outcome of COVID-19 MESHD is primarily driven by the initial severity of infection rather than patient or cancer MESHD characteristics.

    Clinical characteristics and risk factors for severe-critically ill COVID-19 MESHD adult patients in Jiangsu, China: a multiple-centered, retrospective study

    Authors: Jiangnan Zhao; Meiying Zhu; Xin Su; Mao Huang; Yi Yang; Jianan Huang; Ni Songshi; Quan Cao; Qin Gu; Jun Li; Jiashu Li; Wenjing Zhao; Bin Shi; Yi Shi

    doi:10.21203/ Date: 2020-05-12 Source: ResearchSquare

    Background A number of reports have documented the clinical characteristics of patients with severe coronavirus disease 2019 MESHD ( COVID-19 MESHD) in Wuhan. Clinical features of severe-critically ill COVID-19 MESHD patients in Jiangsu, outside Wuhan, remains unknown. Methods This multi-centered retrospective study collected the information of 631 laboratory-confirmed COVID-19 MESHD patients hospitalized at 28 authorized hospitals in Jiangsu province between January 23, 2019 and March 13, 2020. Epidemiological and demographic information, clinical and radiological characteristics, laboratory results and treatment of these patients were analyzed. Results A total of 583 adult patients with laboratory-confirmed COVID-19 MESHD were enrolled for final analysis, including 84 severe-critically ill patients and 499 mild-moderate patients. Median age of the severe-critically ill patients was 57.0 years [interquartile range (IQR), 49.0-65.8], and 50 (59.5%) were males. Multisystemic laboratory abnormalities MESHD were observed on admission in severe-critically ill patients. The severe-critically ill patients showed more noticeable radiologic abnormalities MESHD and more coexisting health issues as compared to mild-moderate patients. Most of the severe-critically ill COVID-19 MESHD patients become deteriorated in two weeks after diagnosis. Age [odds ratio (OR) 1.08, 95% confidence interval (CI) (1.03-1.14)], D-dimer (OR 3.21, 95% CI 1.39-7.40), and lymphocytes (OR 0.28, 95% CI 0.04-0.88) were independently associated with the progression of severe- critically illness MESHD. Conclusions Older age, higher D-dimer levels and less lymphocyte counts on admission are potential risk factors for COVID-19 MESHD patients to develop into severe and critically illness MESHD. The results would help clinicians to identify high-risk patients in advance.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.